Endocrinology · 2013 · 45 citations · 28 references
MedicineOncologyPharmacologyMetastasisMolecular OncologySignal TransductionCancer Cell SignalingMtor Inhibitor TherapyOncogenic Signaling PathwaysSignal Transduction In CancerIn Vivo StudiesMammalian Target Of Rapamycin SignalingMtor InhibitionMtor SignalingMtorc1 SignalingMulti-drug RegimensPi3k-akt-mtor SignalingTumor Susceptibility Genes
Several lines of evidence, including the recent discovery of novel susceptibility genes, point out an important role for the mammalian target of rapamycin (mTOR) signaling pathway in the development of pheochromocytoma. Analyzing a set of pheochromocytomas from patients with different genetic backgrounds, we observed and confirmed a significant overexpression of key mTOR complex (mTORC) signaling mediators. Using selective ATP-competitive inhibitors targeting both mTORC1 and mTORC2, we significantly arrested the in vitro cell proliferation and blocked migration of pheochromocytoma cells as a result of the pharmacological suppression of the Akt/mTOR signaling pathway. Moreover, AZD8055, a selective ATP-competitive dual mTORC1/2 small molecular inhibitor, significantly reduced the tumor burden in a model of metastatic pheochromocytoma using female athymic nude mice. This study suggests that targeting both mTORC1 and mTORC2 is a potentially rewarding strategy and supports the application of selective inhibitors in combinatorial drug regimens for metastatic pheochromocytoma.
28
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Dos D. Sarbassov, Siraj M. Ali, Shomit Sengupta et al. · Molecular Cell · 2006 · 2.6K citations · Full text
Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text
Medicine, Oncology, Pharmacology +13
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
Antonio Di Cristofano, Marika De Acetis, Andrew Koff et al. · Nature Genetics · 2001 · 493 citations